Kyle Doherty

Sac-TMT plus pembrolizumab was safe and effective in recurrent/metastatic cervical cancer.

The FDA has accepted and granted priority review to the BLA seeking the approval of I-DXd in ES-SCLC.

The B7-H4–targeted ADC produced ORRs of 62% and 67% in patients with PROC and endometrial cancer, respectively, in the phase 1 BEHOLD-1 study.

Patients who received first-line niraparib as maintenance therapy had high resolution rates and low number of discontinuations due to hematologic PSEOIs.

With 1 year of additional follow-up, avutometinib plus defactinib showed durable efficacy with no new safety concerns in LGSOC.

During an Onclive Peer Exchange, panelists examined the utility of circulating tumor DNA in bladder cancer and other genitourinary malignancies.

An NDA for neladalkib in TKI-pretreated, advanced, ALK-positive NSCLC was submitted to the FDA.

David R. Wise, MD, PhD, discusses data from a phase 1b study of pasritamig plus docetaxel in mCRPC.

Rana R. McKay, MD, discusses data from the phase 4 OPTYX study of real-world relugolix in prostate cancer.

Cabozantinib was active with no new safety signals in second-line advanced RCC after treatment with frontline checkpoint inhibitor–based therapy.

Cogent Biosciences has submitted an NDA for bezuclastinib for patients with GIST who received prior imatinib.

Cemiplimab plus chemotherapy produced variable outcomes by genomic profile in patients with nonsquamous NSCLC.

Neil Mendhiratta, MD, MS, discusses the treatment landscape for patients with kidney cancer during Kidney Cancer Awareness Month.

The biosimilar Ponlimsi is approved for all reference denosumab indications, and applications for an omalizumab biosimilar candidate have been accepted.

Erda-iDRS was safe and produced early efficacy signals in FGFR-altered NMIBC.

Enolen was safe and feasible for the treatment of patients with early-stage prostate cancer.

Sac-TMT offered significant survival benefits vs docetaxel in pretreated EGFR-mutated NSCLC.

Real-world treatment with relugolix maintained QOL outcomes and had a manageable safety profile in patients with advanced prostate cancer.

Nodal clearance and pleural effusion after osimertinib induction were also identified as predictors of benefit with LCT in EGFR-mutated NSCLC.

Jeffrey Zhong, MD, and Akshit Chitkara, MD, discuss 2 retrospective studies presented during the OncLive National Fellows Forum: Genitourinary Cancer.

The NCCN has added the IBCG risk stratification model for intermediate-risk NMIBC to its Clinical Practice Guidelines in Oncology for bladder cancer.

Neil Mendhiratta, MD, MS, and Toni K. Choueiri, MD, discuss the current and future treatment landscape of kidney cancer during Kidney Cancer Awareness Month.

Nadofaragene firadenovec has been added to the NCCN guidelines in BCG-unresponsive papillary NMIBC without CIS.

PSA decline or control was not found to be concordant with PSMA tumor volume changes among enzalutamide-treated patients with BCR prostate cancer.

Ulka Vaishampayan, MD, FASCO, discusses different novel therapies in development for renal cell carcinoma.

The phase 3 TALAPRO-3 study evaluating talazoparib plus enzalutamide HRR gene–mutated mCSPC met its primary end point.

Lutetium Lu 177 vipivotide tetraxetan was active after treatment with sipuleucel-T in real-world mCRPC.

David B. Solit, MD, discusses ongoing efforts to develop ADCs and other novel treatment approaches beyond EV plus pembrolizumab in urothelial cancer.

The NCCN guidelines in bladder cancer now include nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with papillary-only disease.

Isaac Y. Kim, MD, PhD, MBA, and Anthony V. D'Amico, MD, PhD, discuss radiotherapy, surgery, and emerging strategies in mHSPC.